ArticleJournal of medical case reports2026
Sitosterolemia due to compound heterozygous mutations in ABCG5: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSitosterolemia is an autosomal recessive genetic disorder characterized by hypercholesterolemia and tendon/hip xanthomas, primarily caused by pathogenic mutations in the ABCG5 or ABCG8 gene. CASE PRESENTATION: We report the clinical features and therapeutic outcomes of a 29-year-old Chinese male patient diagnosed with sitosterolemia. The patient first presented with xanthomas in childhood and subsequently developed recurrent hypercholesterolemia in adulthood. Genetic sequencing identified two distinct compound heterozygous mutations in the ABCG5 gene: c.1256G>A (p.Arg419His) and c.751C>T (p.Gln251*). Lipoprotein profiling, including targeted analysis of plant sterols (xenosterols), was performed using gas chromatography-mass spectrometry. Following poor response to statin therapy, the patient was initiated on a low-plant-sterol and low-cholesterol diet, combined with ezetimibe (an NPC1L1 inhibitor). Serum total cholesterol and low-density lipoprotein cholesterol levels normalized within 2 months of this intervention.
conclusionThis case expands the mutational spectrum of sitosterolemia and provides valuable insights for the diagnosis and clinical management of this rare disorder.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.